Jung Jin Seo Chairman, Celltrion Group

Keynote Speech) Seeking oppertunities in risk, K-Bio in the World Pendemics

- Chairman, Korea National Oppera
- Advisory in Financial Strategy, Dawoo Motors
- Expert Adviser, Korea Productivity Center
- Samsung Electro-Mechanics
- Honorary Doctorate, ChungBuk National University
- MA in Business, Konkuk University

David Flores BioCentury President & CEO

- co-Founder, President & CEO, BIOCENTURY
- Advisory Board, Innovation and New Ventures Office (INVO) at Northwestern University
- Advisory Council, Keck Graduate Institute of the Applied Life Sciences
- Management Board, Stanford Graduate School of Business
- Co-Founded BioCentury with Karen Bernstein
- MBA, Stanford University.
- University of California at Berkeley

Cameron Wolfe Associate Professor, Duke University

- Associate Professor, Duke University School of Medicine
- Associate, Duke Initiative for Science & Society
- PI & Key Opinion Leader, Enzychem Lifescience
- Fellow, Infectious Diseases, Medicine, Duke University
- University of Melbourne(MBBS)
- Research on ‘Treatment of Severe COVID19 Patients’ and Lead Phase III clinical trial as part of U.S NIH Project
- HIV infection, Transplant-related infectious diseases, general infectious diseases, Biological and Emergency Preparedness for hospital systems, influenza and respiratory viral pathogens

Joseph P. McMenamin Executive Vice President, W Medical Strategy Group

- Executive Vice President and Chief Legal Officer, W Medical Strategy Group
- Editor-in-Chief, World Asian Medical Journal
- Moderator, New York Health Forum
- General counsel, Virginia Telehealth Network
- Associate Professor of Legal Medicine, Virginia Commonwealth University
- Board of Governors, Health Law Section of the Virginia State Bar
- Internal medicine, Emory University and Grady Memorial Hospital
- School of Law, University of Pennsylvania(JD)
- School of Medicine, University of Pennsylvania(MD)

Andy Jang Co founder & CEO, Starassets Investment

- Co founder & CEO, Starassets Investment
- Managing Director, Atinum Investment
- Analyst in Bio-Pharmaceutical sector, Leading investment & securities
- Boston Scientific, Principal
- Univ. of Wisconsin, Madison Ph.D in Pharmaceutical Sciences

Dimitri Semizarov, PhD Director, Global Medical Affairs Hepatology, Abbvie

- Scientific Director, Hepatology Global Medical team at AbbVie
- 22-year of scientific career spans two therapeutic areas: oncology and hepatology
- Established Personalized Medicine and Genomics & team buiding
- Developed several pipeline drugs, including venetoclax, which is now approved in the US and EU
- Led medical activities for the launch of two HCV drugs, Viekirax/Exviera and Maviret
- Principal inventor on 12 patents
- An author, ‘Genomics in Drug Development’

Matthew Krzywosz, PharmD Associate Scientific Director, Global Medical Affairs Hepatology, Abbvie

- Associate Scientific Director with the Hepatology Global Medical team at AbbVie
- Managed field-based medical team resourcing and design, field effectiveness, scientific communications, medical strategy, and launch planning
- Managed global team of clinical specialists, secured strategic partnerships with the leading patient advocacy organizations
- Managed dozens of clinical trial recruitment campaigns
- Butler University, Doctor of Pharmacy

Wan goo Hwang Managing Director, Samsung Biologics

- CRO Business Team Lead, Vice President Samsung Biologics
- QC Team Lead, Vice President Samsung Biologics
- Diffusion/IIP Technology Team Lead, Vice President, Samsung Electronics
- Samsung Electronics (Diffusion/IIP Technology Team etc.)
- Post Doc Researcher, Basic Science Lab, Seoul National University
- Ph.D. in Chemistry, Seoul National University
- Bachelor in Chemistry, Seoul National University